The strategy of enhancing endogenous NPs and their protective roles in CHF is achieved with the drug sacubitril/valsartan, which augments circulating ANP and BNP by inhibiting of neprilysin that degrades NPs (McMurray et al., 2014). The gene discussed is NPPB; the disease is congestive heart failure.